Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Terunao Iwanaga"'
Autor:
Hidehiro Kamezaki, Hiroshi Yoshikawa, Terunao Iwanaga, Mamoru Tokunaga, Takahiro Maeda, Junichi Senoo, Hiroshi Ohyama, Naoya Kato
Publikováno v:
DEN Open, Vol 4, Iss 1, Pp n/a-n/a (2024)
Abstract Double‐pigtail stents are commonly used for drainage in cholangitis to prevent stent migration. We report a case in which a double pigtail stent had migrated proximally into the bile duct and was successfully retrieved after endoscopic pap
Externí odkaz:
https://doaj.org/article/c66b5e0a21634ac78f93419de205ff4b
Autor:
Takayuki Kondo, Kentaro Fujimoto, Kisako Fujiwara, Sae Yumita, Takamasa Ishino, Keita Ogawa, Miyuki Nakagawa, Terunao Iwanaga, Keisuke Koroki, Hiroaki Kanzaki, Masanori Inoue, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Naoya Kanogawa, Sadahisa Ogasawara, Shingo Nakamoto, Tetsuhiro Chiba, Jun Kato, Keiichi Fujiwara, Naoya Kato
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract The pathogenesis of acute liver failure (ALF) involves cell death. Necroptosis is a newly suggested programmed cell death, and receptor-interacting protein kinase 3 (RIPK3) has been reported as a marker for necroptosis. However, there are fe
Externí odkaz:
https://doaj.org/article/3e4e126c68c14363a57501f3cba46624
Autor:
Hiroaki Kanzaki, Sadahisa Ogasawara, Tomomi Okubo, Norio Itokawa, Ryohei Yoshino, Kentaro Fujimoto, Tadayoshi Kogure, Sae Yumita, Takamasa Ishino, Keita Ogawa, Terunao Iwanaga, Miyuki Nakagawa, Kisako Fujiwara, Ryuta Kojima, Keisuke Koroki, Masanori Inoue, Kazufumi Kobayashi, Naoya Kanogawa, Soichiro Kiyono, Masato Nakamura, Takayuki Kondo, Ryo Nakagawa, Shingo Nakamoto, Ryosuke Muroyama, Ei Itobayashi, Masanori Atsukawa, Jun Kato, Naoya Kato
Publikováno v:
Drugs - Real World Outcomes, Vol 10, Iss 4, Pp 513-520 (2023)
Abstract Background Cabozantinib was found to be effective as a second- or third-line treatment after sorafenib in patients with advanced hepatocellular carcinoma (HCC) in the phase 3 CELESTIAL trial. So far, as immunotherapy has substituted molecula
Externí odkaz:
https://doaj.org/article/48e468f6fb3749d39b8be35352b06933
Autor:
Takayuki Kondo, Kisako Fujiwara, Miyuki Nakagawa, Kentaro Fujimoto, Sae Yumita, Takamasa Ishino, Keita Ogawa, Terunao Iwanaga, Keisuke Koroki, Hiroaki Kanzaki, Masanori Inoue, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Naoya Kanogawa, Sadahisa Ogasawara, Shingo Nakamoto, Tetsuhiro Chiba, Jun Kato, Naoya Kato
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-8 (2023)
Abstract The effect of the combination of atezolizumab and bevacizumab (Atez/Bev) for hepatocellular carcinoma (HCC) on pulmonary arterial hypertension (PAH) is unknown. Estimation of PAH by using computed tomography (CT) has recently been proposed.
Externí odkaz:
https://doaj.org/article/de4d5e3fc7164a0cb2c301cc50e1d96f
Autor:
Sae Yumita, Sadahisa Ogasawara, Miyuki Nakagawa, Susumu Maruta, Tomomi Okubo, Norio Itokawa, Yotaro Iino, Masamichi Obu, Yuki Haga, Atsuyoshi Seki, Tadayoshi Kogure, Takamasa Ishino, Keita Ogawa, Kisako Fujiwara, Terunao Iwanaga, Naoto Fujita, Takafumi Sakuma, Ryuta Kojima, Hiroaki Kanzaki, Keisuke Koroki, Masanori Inoue, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Naoya Kanogawa, Tomoko Saito, Takayuki Kondo, Ryo Nakagawa, Shingo Nakamoto, Ryosuke Muroyama, Tetsuhiro Chiba, Ei Itobayashi, Masanori Atsukawa, Yoshihiro Koma, Ryosaku Azemoto, Kenji Ito, Hideaki Mizumoto, Jun Kato, Naoya Kato
Publikováno v:
BMC Gastroenterology, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Background Hyperprogressive disease (HPD) is a phenomenon with greatly accelerated tumor growth and clinical deterioration rates compared to pre-therapy, in patients treated with immune checkpoint inhibitors (ICI). The aim of this study is t
Externí odkaz:
https://doaj.org/article/e6438030eab2449d8f1c4414595c6e53
Autor:
Naoya Kanogawa, Sadahisa Ogasawara, Susumu Maruta, Yotaro Iino, Masamichi Obu, Takamasa Ishino, Keita Ogawa, Sae Yumita, Terunao Iwanaga, Hidemi Unozawa, Miyuki Nakagawa, Kisako Fujiwara, Takafumi Sakuma, Naoto Fujita, Ryuta Kojima, Hiroaki Kanzaki, Keisuke Koroki, Kazufumi Kobayashi, Masanori Inoue, Soichiro Kiyono, Masato Nakamura, Takayuki Kondo, Tomoko Saito, Ryo Nakagawa, Shingo Nakamoto, Ryosuke Muroyama, Tetsuhiro Chiba, Ei Itobayashi, Yoshihiro Koma, Ryosaku Azemoto, Jun Kato, Naoya Kato
Publikováno v:
BMC Gastroenterology, Vol 23, Iss 1, Pp 1-10 (2023)
Abstract Purpose Ramucirumab was shown to be effective as a second-line treatment after sorafenib in patients with advanced hepatocellular carcinoma (HCC) with alpha-fetoprotein levels > 400 ng/mL in a worldwide phase 3 trial. Ramucirumab is used in
Externí odkaz:
https://doaj.org/article/ec4cc9154a2f40df8dcaa61493fe4d89
Autor:
Takayuki Kondo, Kisako Fujiwara, Miyuki Nakagawa, Hidemi Unozawa, Terunao Iwanaga, Takafumi Sakuma, Naoto Fujita, Keisuke Koroki, Hiroaki Kanzaki, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Naoya Kanogawa, Tomoko Saito, Sadahisa Ogasawara, Eiichiro Suzuki, Yoshihiko Ooka, Shingo Nakamoto, Tetsuhiro Chiba, Makoto Arai, Jun Kato, Naoya Kato
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-9 (2022)
Abstract The screening of gastroesophageal varices (GEV) is critical in hepatocellular carcinoma (HCC) management. Contrast-enhanced computed tomography (CECT) is often performed in patients with HCC. Therefore, this study aimed to examine the use of
Externí odkaz:
https://doaj.org/article/195628a7649a45c4815c5e21e0540138
Autor:
Kazufumi Kobayashi, Sadahisa Ogasawara, Aya Takahashi, Yuya Seko, Hidemi Unozawa, Rui Sato, Shunji Watanabe, Michihisa Moriguchi, Naoki Morimoto, Satoshi Tsuchiya, Kenji Iwai, Masanori Inoue, Keita Ogawa, Takamasa Ishino, Terunao Iwanaga, Takafumi Sakuma, Naoto Fujita, Hiroaki Kanzaki, Keisuke Koroki, Masato Nakamura, Naoya Kanogawa, Soichiro Kiyono, Takayuki Kondo, Tomoko Saito, Ryo Nakagawa, Eiichiro Suzuki, Yoshihiko Ooka, Shingo Nakamoto, Akinobu Tawada, Tetsuhiro Chiba, Makoto Arai, Tatsuo Kanda, Hitoshi Maruyama, Kengo Nagashima, Jun Kato, Norio Isoda, Takeshi Aramaki, Yoshito Itoh, Naoya Kato
Publikováno v:
Liver Cancer, Pp 1-13 (2021)
Background and Aims: The prognosis of patients with advanced hepatocellular carcinoma (HCC) is expected to improve as multiple molecular target agents (MTAs) are now available. However, the impact of the availability of sequential MTAs has not been f
Externí odkaz:
https://doaj.org/article/3d27bd60476f43d0ad39fa2137391db5
Autor:
Shohei Mukai, Hiroaki Kanzaki, Sadahisa Ogasawara, Takamasa Ishino, Keita Ogawa, Miyuki Nakagawa, Kisako Fujiwara, Hidemi Unozawa, Terunao Iwanaga, Takafumi Sakuma, Naoto Fujita, Keisuke Koroki, Kazufumi Kobayashi, Naoya Kanogawa, Soichiro Kiyono, Masato Nakamura, Takayuki Kondo, Tomoko Saito, Ryo Nakagawa, Eiichiro Suzuki, Yoshihiko Ooka, Ryosuke Muroyama, Shingo Nakamoto, Akinobu Tawada, Tetsuhiro Chiba, Makoto Arai, Jun Kato, Manayu Shiina, Masayuki Ota, Jun‐ichiro Ikeda, Yuichi Takiguchi, Masayuki Ohtsuka, Naoya Kato
Publikováno v:
JGH Open, Vol 5, Iss 11, Pp 1266-1274 (2021)
Abstract Background and Aim Immune checkpoint inhibitors and their combination with other agents have recently been available in advanced hepatocellular carcinoma (HCC). Hence, a thorough understanding of the tumor microenvironment based on tumor sam
Externí odkaz:
https://doaj.org/article/e082e4c91a2142358c016fb7ff695a59
Autor:
Ryoi Yoshida, Keisuke Koroki, Hirokazu Makishima, Sadahisa Ogasawara, Takamasa Ishino, Keita Ogawa, Miyuki Nakagawa, Kisako Fujiwara, Hidemi Unozawa, Terunao Iwanaga, Naoto Fujita, Takafumi Sakuma, Hiroaki Kanzaki, Kazufumi Kobayashi, Naoya Kanogawa, Soichiro Kiyono, Masato Nakamura, Takayuki Kondo, Tomoko Saito, Ryo Nakagawa, Eiichiro Suzuki, Yoshihiko Ooka, Shingo Nakamoto, Akinobu Tawada, Tetsuhiro Chiba, Makoto Arai, Takashi Kaneko, Masaru Wakatsuki, Jun Kato, Hiroshi Tsuji, Naoya Kato
Publikováno v:
Case Reports in Oncology, Vol 14, Iss 2, Pp 1103-1110 (2021)
Macrovascular invasion (MVI), including portal vein tumor thrombosis (PVTT), is strongly associated with poor prognosis in patients with hepatocellular carcinoma (HCC). While recommended standard treatment for patients with advanced HCC is systemic t
Externí odkaz:
https://doaj.org/article/a26491db54d54c3589460f579d52e795